Navigation Links
Using fish to illuminate the architecture of inherited disease
Date:5/24/2010

Durham, N.C. A research team led by scientists from the Duke University Medical Center has developed a way to simultaneously look at the effects of 125 mutations occurring on 14 different genes. They used zebrafish as a model to analyze the function of every known mutation in an inherited syndrome called BBS, Bardet-Biedl Syndrome.

Being able to analyze the functions and interactions of all mutations in a complex inherited disease could have implications for a broad range of disorders. The study found that, while mutations at one of at least 14 genes are responsible for the disorder, mutations elsewhere in the genome may modify the severity and diversity of the symptoms.

"The human genome project and new technologies can help us identify mutations in patients' genomes, but the challenge is how to interpret such variation and how to use it to improve the ability to predict what this means with respect to a patient's clinical presentation," said senior author Nicholas Katsanis, Ph.D., Jean and George Brumley Jr., M.D., Professor of Developmental Biology, Professor of Pediatrics and Cell Biology, and Director of the Duke Center for Human Disease Modeling. "Our work demonstrates that it is possible to develop functional bioassays using a vertebrate model that predicts whether a mutation has a role in a complex disease, like Bardet-Biedl syndrome, which we studied."

The study was published online during the week of May 24 in the Proceedings of the National Academy of Sciences.

BBS is an interesting disease to use as a study model because it involves a number of different traits that are highly variable among patients, said Katsanis, whose endowed professorship is in the Neonatal-Perinatal Research Institute at Duke. People with BBS may have retinopathy, obesity, mental retardation, more than the usual number of fingers or toes, and other distinct traits. BBS has become something of a workhorse for understanding variability of disease in humans, he said.

Simultaneously studying all the mutations in BBS led to some notable discoveries. Contrary to popular scientific belief, some mutations in BBS not only cause the loss of function of a protein, they actually influence the "good" remaining copies of the protein. In addition, the researchers saw that a subset of commonly occurring versions of some genes (called alleles) can be detrimental to protein function. The common alleles also can interact with strong, rare alleles to determine a trait.

"We speculate that such interactions are probably widespread across genetic disorders," Katsanis said. "Indeed, this might help settle a 100-year-old argument about common versus rare mutations and how they might underlie human genetic disorders. Perhaps not surprisingly, the answer is both, in a context-dependent fashion."

Katsanis is a world expert in ciliopathies such as BBS, in which the primary cilium (protrusion) of cells is abnormal and leads to a host of problems. About one child in 1,000 live births will have a ciliopathy, an incidence that is in the range of Down's syndrome, said Katsanis.

Katsanis said that the complex architecture of BBS probably is not unique to this disorder so the approach used by these researchers could improve understanding of a wide variety of human traits.

The researchers did in vivo tests in fish to learn whether they would develop defects if they had specific mutations and then validated their results with in vitro tests on cells in a lab dish to learn whether the aberrant activity in zebrafish embryos could be explained by defective behavior in mammalian cells.

Importantly, by comparing their data with previous clinical studies, they found their tools to be both highly sensitive and highly accurate, correctly predicting the effect of mutations at 98 percent, with a false-positive rate of less than 10 percent. "These numbers are quite critical, because they mean that we can use this approach to interpret information in the clinical setting; these percentages should be good enough for application in clinical labs," Katsanis said.

"A next step is to develop similar tools to let us evaluate various human genetic mutations within the context of their functions," Katsanis said. "Genotype must have a predictive value or it doesn't tell us much. Knowing all of the disease-related variants in a genome is only a starting point, because our work suggests that there is complexity that many do not yet appreciate in disease architecture."


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Related biology news :

1. UCLA engineer gets $4 million from Department of Energy to convert CO2 to liquid fuel using electricity
2. Using remote sensing to track invasive trees
3. Using a pests chemical signals to control it
4. New plastic-like materials may say shhhh to hush disease-causing microbes
5. Project for sailing vessels to maneuver in ports using electric energy from wind
6. K-State professor using NSF award to study the impact of nitrogen deposition on global change
7. Scientists create artificial human skin with biomechanical properties using tissue engineering
8. Beetles stand out using Avatar tech
9. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
10. Development of new anti-cancer gene therapy approach using lentiviral vectors
11. IU researchers target vascular disease linked to cancer-causing gene mutation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... SEATTLE , April 5, 2017  The Allen ... the Allen Cell Explorer: a one-of-a-kind portal and dynamic ... large-scale 3D imaging data, the first application of deep ... edited human stem cell lines and a growing suite ... the platform for these and future publicly available resources ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... of a United States multicenter, prospective clinical study that demonstrates the accuracy ... test capable of identifying clinically significant acute bacterial and viral respiratory tract ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... its endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression ... guides is transformative for performing systematic gain-of-function studies. , This complement to ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology: